Combining radiolabelled therapies for neuroendocrine neoplasms

Neuroendocrine liver metastases often require multiple modes of treatment to attain disease control, which can utilize various forms of radiolabelled agents either delivered systemically or preferentially towards the liver. A recent trial suggested both safety and efficacy of a novel approach of combining the two to provide a radiation ‘boost’ to hepatic deposits.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Frilling, A. et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 15, e8–21 (2014).

    Article  Google Scholar 

  2. 2.

    Dasari, A. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335–1342 (2017).

    Article  Google Scholar 

  3. 3.

    Chen, J. X. et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc. Intervent. Radiol. 40, 69–80 (2017).

    Article  Google Scholar 

  4. 4.

    Kratochwil, C. et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr. Relat. Cancer 18, 595–602 (2011).

    CAS  Article  Google Scholar 

  5. 5.

    Kennedy, A. et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB 17, 29–37 (2015).

    Article  Google Scholar 

  6. 6.

    Frilling, A. et al. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB 21, 773–783 (2019).

    Article  Google Scholar 

  7. 7.

    Braat, A. J. A. T. et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 21, 561–570 (2020).

    CAS  Article  Google Scholar 

  8. 8.

    Strosberg, J. et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).

    CAS  Article  Google Scholar 

  9. 9.

    Pavel, M. et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103, 172–185 (2016).

    CAS  Article  Google Scholar 

  10. 10.

    Kennedy, A. et al. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: Expert consensus. J. Gastrointest. Oncol. 8, 1079–1099 (2017).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Andrea Frilling.

Ethics declarations

Competing interests

A.F. reports receiving speaker honoraria from SIRTEX. A.K.C. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Frilling, A., Clift, A.K. Combining radiolabelled therapies for neuroendocrine neoplasms. Nat Rev Endocrinol 16, 347–348 (2020).

Download citation


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing